Bacterial endocarditis
diseaseOn this page
Also known as Bacteria caused endocarditis (disease)Bacteria endocarditis (disease)bacterial endocarditis (disease)
Summary
Bacterial endocarditis (MONDO:0006669) is a disease and 1 clinical trial. Top therapeutic interventions include daptomycin. A subtype of infective endocarditis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | bacterial endocarditis |
| Mondo ID | MONDO:0006669 |
| EFO | EFO:1000830 |
| MeSH | D004697 |
| ICD-11 | 1924438986 |
| NCIT | C128359 |
| SNOMED CT | 301183007 |
| UMLS | C0014121 |
| MedGen | 41779 |
| GARD | 0024456 |
| MedDRA | 10004019 |
| Is cancer (heuristic) | no |
Also known as: Bacteria caused endocarditis (disease) · Bacteria endocarditis (disease) · bacterial endocarditis · bacterial endocarditis (disease)
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of infective endocarditis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › endocardium disorder › endocarditis › infective endocarditis › bacterial endocarditis
Related subtypes (2): subacute bacterial endocarditis, mycotic endocarditis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Daptomycin | Approved (phase 4) |
| Penicillin V | Approved (phase 4) |
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00093067 | PHASE3 | COMPLETED | Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DAPTOMYCIN | 4 | 1 |
| CHEMBL1649722 | 0 | 1 |
| CHEMBL4286784 | 0 | 1 |
| CHEMBL4744444 | 0 | 1 |
Related Atlas pages
- Drugs: Daptomycin